The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells
Open Access
- 19 September 2013
- journal article
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 95 (1) , 95-104
Abstract
Advanced SM is an incurable neoplasm with short survival time. So far, no effective therapy is available for these patients. We and others have shown recently that neoplastic MC in ASM and MCL express antiapoptotic Mcl-1, Bcl-2, and Bcl-xL. In this study, we examined the effects of the pan-Bcl-2 family blocker obatoclax (GX015-070) on primary neoplastic MC, the human MC leukemia cell line HMC-1, and the canine mastocytoma cell line C2. Obatoclax was found to inhibit proliferation in primary human neoplastic MC (IC50: 0.057 μM), in HMC-1.2 cells expressing KIT D816V (IC50: 0.72 μM), and in HMC-1.1 cells lacking KIT D816V (IC50: 0.09 μM), as well as in C2 cells (IC50: 0.74 μM). The growth-inhibitory effects of obatoclax in HMC-1 cells were accompanied by an increase in expression of Puma, Noxa, and Bim mRNA, as well as by apoptosis, as evidenced by microscopy, TUNEL assay, and caspase cleavage. Viral-mediated overexpression of Mcl-1, Bcl-xL, or Bcl-2 in HMC-1 cells was found to introduce partial resistance against apoptosis-inducing effects of obatoclax. We were also able to show that obatoclax synergizes with several other antineoplastic drugs, including dasatinib, midostaurin, and bortezomib, in producing apoptosis and/or growth arrest in neoplastic MC. Together, obatoclax exerts major growth-inhibitory effects on neoplastic MC and potentiates the antineoplastic activity of other targeted drugs. Whether these drug effects can be translated to application in patients with advanced SM remains to be determined.Keywords
Funding Information
- The Mastocytosis Society
- Medical University of Vienna
- Austrian Science Fund (#P21173-B13, SFB-F4704-B20)
This publication has 51 references indexed in Scilit:
- Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent processBlood, 2012
- Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemiaBlood, 2012
- Identification of Oncostatin M as a STAT5-Dependent Mediator of Bone Marrow Remodeling in KIT D816V-Positive Systemic MastocytosisThe American Journal of Pathology, 2011
- Non‐peptidic small molecule inhibitors against Bcl‐2 for cancer therapyJournal of Cellular Physiology, 2008
- Mast cells and mastocytosisBlood, 2008
- BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosisMolecular Cancer Therapeutics, 2008
- The BH3-only protein Puma plays an essential role in cytokine deprivation–induced apoptosis of mast cellsBlood, 2007
- Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cellsVeterinary Immunology and Immunopathology, 2007
- Apoptosis Protection by the Epo Target Bcl-XL Allows Factor-Independent Differentiation of Primary ErythroblastsCurrent Biology, 2002
- Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.Journal of Clinical Investigation, 1993